Newsroom

Jeff Baxter and David E. Anderson, Ph.D., discuss updated Phase 2a (Part B) data of VBI-1901 in recurrent GBM patients, as presented at SNO 2020.

Adam Finn, M.D., Ph.D., discusses Data from the Sci-B-Vac® Phase 3 program at EASL.

VBI discusses preclinical coronavirus program data and selection of clinical candidates with potential as one-dose vaccines.

David E. Anderson, Ph.D., discusses updated Part B data from the VBI's ongoing Phase 1/2a study of VBI-1901.

Hepatitis B is a disease of the liver caused by the hepatitis B virus (“HBV”) characterized by inflammation, injury, and even cell death.